Oncology: Driving precision cancer research and clinical trials

Modern medicine, particularly in the complex field of oncology, demands increasingly precise and comprehensive insights into the molecular underpinnings of cancer. At OHMX.bio, we understand that achieving true precision medicine requires cutting-edge applications and meticulous data. We provide a full spectrum of advanced omics solutions designed to accelerate both fundamental oncology research and the rigorous demands of clinical trial support. Leveraging advanced sequencing, proteomics, and bioinformatics, we empower researchers and clinicians to unravel tumor heterogeneity, identify actionable targets, and advance personalized medicine strategies.
Contact our experts

Comprehensive omics for oncology R&D

Our expertise in oncology spans a wide range of research and development applications, providing the detailed molecular data necessary for groundbreaking discoveries:

Variant Analysis

We offer in-depth genomic profiling to identify somatic and germline mutations, single nucleotide polymorphisms (SNPs), copy number variations (CNVs), and complex structural variants (SVs) that drive cancer initiation, progression, and therapeutic resistance. Our high-accuracy sequencing platforms, including the Element Biosciences AVITI sequencer, combined with advanced bioinformatics pipelines, ensure unparalleled precision in detecting even rare mutations.

Proteomic Characterization

Our advanced mass spectrometry-based proteomics services enable the identification and quantification of thousands of proteins, including post-translational modifications. This provides a functional layer of insight into cancer biology, aiding in biomarker discovery, understanding signaling pathways, and assessing drug effects at the protein level.

Epigenetic Insights

We explore DNA methylation patterns and other epigenetic modifications that play critical roles in gene regulation and cancer development. Our Oxford Nanopore long-read sequencing technology allows for direct detection of base modifications, offering a comprehensive view of epigenetic landscapes.

Translational Research (RIBO-seq)

Our world-renowned ribosome profiling (RIBO-seq) services provide a real-time snapshot of protein synthesis, bridging the gap between transcriptomics and proteomics. This is invaluable for identifying actively translated neoantigens, understanding translational dysregulation in cancer, and discovering novel therapeutic targets.

Contact our experts
OHMX.bio - Innovative omics solutions

Seamless Integration: From wet lab to actionable insights

At OHMX.bio, our expertise extends beyond generating high-quality data. We pride ourselves on the seamless integration of wet-lab experimentation and dry-lab bioinformatics, ensuring that the data generated is not only robust but also directly translatable into usable, actionable insights. Our experienced wet-lab scientists meticulously handle sample preparation and experimental execution, while our dedicated team of bioinformaticians, with deep expertise in algorithm development, statistical modeling, and data visualization, processes and interprets complex omics data. This integrated approach guarantees that every project benefits from a comprehensive, end-to-end workflow, transforming raw biological outputs into clear, interpretable results that truly drive your oncology research and clinical objectives forward.
Contact our experts
OHMX.bio_Innovative omics solutions_Scientific Excellence

Supporting oncology clinical trials

OHMX.bio is a trusted partner for clinical trials, providing robust, high-quality omics data and analytical support tailored to meet regulatory and diagnostic requirements. Our services are designed to ensure reliability and actionability for critical clinical applications:

Biomarker Discovery & Validation

We identify and validate predictive and prognostic biomarkers for patient stratification, treatment response monitoring, and disease progression tracking. Our capabilities support the seamless transition of biomarkers from discovery to clinical validation.

Companion Diagnostics (CDx) Support

We offer comprehensive services to support the discovery, evaluation, and optimization of CDx solutions, ensuring that the right treatment reaches the right patient. Our integrated approach leverages NGS, mass spectrometry, and qPCR to develop robust and clinically relevant biomarker assays.

Minimal Residual Disease (MRD) Testing

Our highly sensitive MRD testing solutions, utilizing both NGS and qPCR technologies, enable the detection of very low levels of residual cancer cells after treatment. This is crucial for guiding personalized patient management and improving outcomes in oncology and hematology.

Quality and Compliance

Our commitment to excellence is reflected in our adherence to globally recognized quality standards, including ISO 9001 and ISO 27001 certifications, GCLP standards, and operations in GMP-accredited laboratories. This ensures the reliability of our services for regulated environments.

Contact our experts

Case studies

Case study 1: Characterization of shared neoantigens in mismatch repair deficient endometrial cancer

The identification of neoantigens, unique peptides presented on the surface of cancer cells, is paramount for the development of effective cancer immunotherapies. Their accurate characterization is a key challenge in precision oncology.
In the study “Characterization of shared neoantigens landscape in Mismatch Repair Deficient Endometrial Cancer” (De Paolis, E., Nero, C., Micarelli, E. et al., npj Precis. Onc. 8, 283 (2024)), OHMX.bio’s expertise played a significant role. This research focused on Mismatch Repair Deficient (MMRd) Endometrial Cancer, a subtype known for its high mutational burden and potential for neoantigen generation. By combining genomic data with ribosome profiling (RIBO-seq), the researchers were able to identify actively translated neoantigens. This approach is superior to relying solely on genomic predictions, as RIBO-seq directly confirms which mutated sequences are indeed translated into proteins that can be presented to the immune system. The study successfully characterized the landscape of shared neoantigens in this cancer type, providing a more refined and validated list of immunogenic targets. This case study exemplifies OHMX.bio’s capability to provide deep molecular insights that directly inform the development of novel, broadly applicable immunotherapies, ultimately contributing to more effective treatment strategies for cancer patients.
Contact our experts

Partner with OHMX.bio for your oncology innovations

OHMX.bio is your dedicated partner in advancing oncology research and clinical applications. With our extensive expertise in cutting-edge omics technologies, robust bioinformatics, and commitment to quality, we provide the precise and actionable insights needed to accelerate your journey from discovery to clinical impact.

Contact us today to discuss how our comprehensive oncology solutions can empower your next breakthrough.
OHMX.bio_Innovative omics solutions_Tailored Personal Approach

Let’s get in touch!

Are you curious about how we can work on your -omics challenges together? Fill out the form below!
Our experts will reply within 2 working days to freely discuss your omics project.

Our publications using our cell en gene therapies

  1.  
OHMX..bio logo
Your partner for innovative OMICS solutions.
Linkedin Google
OHMX.bio is part of
the anacura group.
© 2026 OHMX.bio

Proudly created by DauntlessDonkey

TESTING SERVICES

EXPERTISE

OHMX.bio

CONTACT

  • Belgium
    Noorwegenstraat 4
    9940 Evergem
  • Switzerland
    Phenyl - 2nd floor, Route de la Corniche 3, 1066 Epalinges
Oxford Nanopore Service Certified
logo-cir
Registered supplier logo_Scientist.com